During a trip to China in 2012, Paul Yu, MD, PhD, had the eye-opening experience of meeting patients with fibrodysplasia ossificans progressiva (FOP) for the first time at a specialty clinic at Shanghai Tongji Hospital.
Predicting and examining which mutations in a cardiomyopathy gene are benign and which ones are harmful.
BWH is leading the way in using a more systematic approach to treat HCM patients.
A study led by Barry H. Paw, MD, PhD, with Yvette Y. Yien, PhD, BWH Division of Hematology, discovered…
TIMI celebrates 30 years of excellence.
BWH physicians and researchers participate in the European Society of Cardiology Congress.
It's not every day that the leaders of the two most prominent cardiology and cardiovascular organizations in the United States come from the same hospital.
Mary Walsh is BWH's first patient to undergo a transcatheter aortic valve replacement without general anesthesia.
The Cardio-Oncology Program, a joint collaboration between BWH and Dana-Farber Cancer Institute, focuses on the cardiovascular side effects of cancer therapy while maximizing cardiovascular outcomes for cancer survivors.
A team of researchers has discovered certain proteins in osteoclasts, a precursor to bone, that may be used in helping to destroy cardiovascular calcification by dissolving mineral deposits.
BWH leadership and cardiovascular staff came together Jan. 22 to celebrate the launch of BWH’s Heart & Vascular Center, a fully integrated and aligned service dedicated to delivering life-giving breakthroughs.
An international symposium assembled at BWH to discuss heart disease.
The Center for Advanced Heart Disease at BWH is taking an innovative approach to caring for some of its sickest patients.
The Cardiovascular Inflammation Reduction Trial studies whether a drug used to treat rheumatoid arthritis can also reduce recurrent cardiovascular events.
Richard Blumberg, MD, humbly refers to his hemophilia drug discovery as “a beautiful mistake.”